Approximately 20–35% of melanoma and non-adenocarcinoma lung tumor cell lines had a reduced IFN-γ sensitivity, while ~10% of lung adenocarcinoma cell lines were resistant to IFN-γ treatment. This evidence concerns the gene IFNG and melanoma.